Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
STAA
vs
S&P 500
STAA
S&P 500
Over the past 12 months, STAA has underperformed S&P 500, delivering a return of -8% compared to S&P 500's +10% growth.
Stocks Performance
STAA vs S&P 500
Performance Gap
STAA vs S&P 500
Create a free account · No card needed
Performance By Year
STAA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
STAAR Surgical Co
Glance View
STAAR Surgical makes implantable lenses for the eye, mainly used to correct nearsightedness and astigmatism. Its core product is a Collamer lens that an eye surgeon places inside the eye, giving patients a vision-correction option that does not reshape the cornea like LASIK. The company sells these lenses to ophthalmic surgeons, eye clinics, hospitals, and distributors around the world. It makes money when those medical providers buy its lens implants and related products for refractive procedures. STAAR’s business depends on elective eye surgery, so it sits in the medical-device part of the vision-care market rather than the eyewear or drug business. What makes STAAR different is that it is focused on a single, specialized procedure: implantable lenses for refractive correction. That gives it a narrow but important role in eye care, where surgeons use its products as an alternative for patients who are not ideal candidates for laser vision correction.
Create a free account · No card needed
